Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database
Tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb), remains a leading infectious disease-related cause of death worldwide, necessitating the development of new and improved treatment regimens. Nonclinical evaluation of candidate drug combinations via the relapsing mouse model (RMM) is an important step in regimen development, through which candidate regimens that provide the greatest decrease in the probability of relapse following treatment in mice may be identified for further development. Although RMM studies are a critical tool to evaluate regimen efficacy, making comprehensive "apples to apples" comparisons of regimen performance in the RMM has been a challenge in large part due to the need to evaluate and adjust for variability across studies arising from differences in design and execution. To address this knowledge gap, we performed a model-based meta-analysis on data for 17 unique regimens obtained from a total of 1592 mice across 28 RMM studies. Specifically, a mixed-effects logistic regression model was developed that described the treatment duration-dependent probability of relapse for each regimen and identified relevant covariates contributing to interstudy variability. Using the model, covariate-normalized metrics of interest, namely, treatment duration required to reach 50% and 10% relapse probability, were derived and used to compare relative regimen performance. Overall, the model-based meta-analysis approach presented herein enabled cross-study comparison of efficacy in the RMM and provided a framework whereby data from emerging studies may be analyzed in the context of historical data to aid in selecting candidate drug combinations for clinical evaluation as TB drug regimens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 66(2022), 3 vom: 15. März, Seite e0179321 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Berg, Alexander [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitubercular Agents |
|---|
| Anmerkungen: |
Date Completed 23.03.2022 Date Revised 23.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/AAC.01793-21 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336330189 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336330189 | ||
| 003 | DE-627 | ||
| 005 | 20231225231911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/AAC.01793-21 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1121.xml |
| 035 | |a (DE-627)NLM336330189 | ||
| 035 | |a (NLM)35099274 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Berg, Alexander |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.03.2022 | ||
| 500 | |a Date Revised 23.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb), remains a leading infectious disease-related cause of death worldwide, necessitating the development of new and improved treatment regimens. Nonclinical evaluation of candidate drug combinations via the relapsing mouse model (RMM) is an important step in regimen development, through which candidate regimens that provide the greatest decrease in the probability of relapse following treatment in mice may be identified for further development. Although RMM studies are a critical tool to evaluate regimen efficacy, making comprehensive "apples to apples" comparisons of regimen performance in the RMM has been a challenge in large part due to the need to evaluate and adjust for variability across studies arising from differences in design and execution. To address this knowledge gap, we performed a model-based meta-analysis on data for 17 unique regimens obtained from a total of 1592 mice across 28 RMM studies. Specifically, a mixed-effects logistic regression model was developed that described the treatment duration-dependent probability of relapse for each regimen and identified relevant covariates contributing to interstudy variability. Using the model, covariate-normalized metrics of interest, namely, treatment duration required to reach 50% and 10% relapse probability, were derived and used to compare relative regimen performance. Overall, the model-based meta-analysis approach presented herein enabled cross-study comparison of efficacy in the RMM and provided a framework whereby data from emerging studies may be analyzed in the context of historical data to aid in selecting candidate drug combinations for clinical evaluation as TB drug regimens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Mycobacterium | |
| 650 | 4 | |a model-based meta-analysis | |
| 650 | 4 | |a modeling and simulation | |
| 650 | 4 | |a relapsing mouse model | |
| 650 | 4 | |a tuberculosis | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 700 | 1 | |a Clary, James |e verfasserin |4 aut | |
| 700 | 1 | |a Hanna, Debra |e verfasserin |4 aut | |
| 700 | 1 | |a Nuermberger, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Lenaerts, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Ammerman, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Ramey, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Hartley, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Hermann, David |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 66(2022), 3 vom: 15. März, Seite e0179321 |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2022 |g number:3 |g day:15 |g month:03 |g pages:e0179321 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/AAC.01793-21 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2022 |e 3 |b 15 |c 03 |h e0179321 | ||